Optimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary
Open Access
- 11 September 2026
- journal article
- editorial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (11) , 2179-2183
Abstract
Historically, dose-finding in oncology drug development has been guided by maximum tolerated dose (MTD) principles, often exposing patients to unnecessary toxicity without achieving additional effi...Keywords
This publication has 12 references indexed in Scilit:
- Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysisBlood, 2025
- Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in MyelofibrosisClinical Pharmacology & Therapeutics, 2025
- The Retrofit: Lessons From Sotorasib's Dosing ConundrumJournal of Clinical Oncology, 2025
- Momelotinib: Mechanism of action, clinical, and translational scienceClinical and Translational Science, 2024
- Dosage Optimization: A Regulatory Perspective for Developing Oncology DrugsClinical Pharmacology & Therapeutics, 2024
- Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to PatientsJournal of Clinical Oncology, 2022
- A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisBlood Advances, 2022
- Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP studyLeukemia & Lymphoma, 2020
- Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling MethodsCPT: Pharmacometrics & Systems Pharmacology, 2013
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia, 2013